For the year ending 2025-12-31.
| Income Statement | 2025-12-31 | 2024-12-31 | ||
|---|---|---|---|---|
| Revenue | 0 | - | ||
| Research and development | 109,157 | 169,310 | ||
| General and administrative | 47,216 | 59,055 | ||
| Total operating expenses | 156,373 | 228,365 | ||
| Loss from operations | -156,373 | -228,365 | ||
| Interest and other income (expense), net | 11,416 | 21,085 | ||
| Interest expense | 2,559 | 3,024 | ||
| Loss on extinguishment of debt (note 7) | -1,828 | - | ||
| Net loss | -149,344 | -210,304 | ||
| Net unrealized loss on short-term investments | -336 | -24 | ||
| Total other comprehensive loss | -336 | -24 | ||
| Comprehensive loss | -149,680 | -210,328 | ||
| Basic EPS | -2.43 | -3.47 | ||
| Diluted EPS | -2.43 | -3.47 | ||
| Basic Average Shares | 61,366,887 | 60,538,639 | ||
| Diluted Average Shares | 61,366,887 | 60,538,639 | ||
PLIANT THERAPEUTICS, INC. (PLRX)
PLIANT THERAPEUTICS, INC. (PLRX)